跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
DUAVIVE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
DUAVIVE
Authorized
STANDARD
DUAVIVE
Pfizer Canada Ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
80626d38ae605d32
Company
Pfizer Canada Ulc
Type
Standard
Approval Details
Approval Id
80626d38ae605d32
Drug Approval Canada Name
DUAVIVE
Product Name
DUAVIVE
Status
Marketed
Status Date
2023-06-09
Original Market Date
2016-12-20
Din
02432854
Drug Class
Human
Dosage Form
Tablet (Immediate And Extended Release)
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:16.12
Atc Original
G03CC07 CONJUGATED ESTROGENS AND BAZEDOXIFENE
Atc Name
g 03 cc 07
Aig Number
0256130001
Company Name
Pfizer Canada Ulc
Company Address
17300 Trans-Canada Highway, Kirkland, Quebec, Canada, H9J 2M5
Company Detail Path
/organization/pfizer-canada-ulc
Company Information
Pharmaceutical Company Name
Pfizer Canada Ulc
Country Name
Canada
Province Name
Quebec
City Name
kirkland,quebec,country_ca
Address
17300 rte Transcanadienne
Active Ingredients
CONJUGATED ESTROGENS
0.45 MG
BAZEDOXIFENE (BAZEDOXIFENE ACETATE)
20 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
80626d38ae605d32
Type
Standard
Back to Health Canada Approvals